Carolina Liquid Chemistries Corp
Letter data
- Company
- Carolina Liquid Chemistries Corp
- Recipient
- Patricia A.G. Shugart, Philip Shugart | Chief Operating Officer, CEO | Carolina Liquid Chemistries Corp | 313 Gallimore Dairy Rd. | Greensboro | , | NC | 27409 | United States | pattigaull@aol.com
- Issue date
- 2020-11-02
- Posted date
- Not available
- FDA office
- Office of Medical Devices and Radiological Health Operations Division 3/West
- Subject
- Not available
- Product
- Not available
- CMS ID
- 573596
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Carolina Liquid Chemistries Corp
MARCS-CMS 573596 —
November 02, 2020
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Delivery Method:
VIA Electronic Mail
Recipient:
Recipient Name
Patricia A.G. Shugart, Philip Shugart
Recipient Title
Chief Operating Officer, CEO
Carolina Liquid Chemistries Corp
313 Gallimore Dairy Rd.
Greensboro
,
NC
27409
United States
pattigaull@aol.com
Issuing Office:
Office of Medical Devices and Radiological Health Operations Division 3/West
United States
Dear Ms. & Mr. Shugart,
The Food and Drug Administration has completed an evaluation of your corrective actions in response to a Warning Letter dated 7/31/2019. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Jessica Mu
Compliance Branch Director
Office of Medical Devices and Radiological Health Operations
Division 3/West
Content current as of:
11/18/2020